Literature DB >> 25914343

McArdle Disease: Update of Reported Mutations and Polymorphisms in the PYGM Gene.

Gisela Nogales-Gadea1, Astrid Brull2,3, Alfredo Santalla4,5, Antoni L Andreu2,3, Joaquin Arenas5,6, Miguel A Martín3,5,6, Alejandro Lucia6,7, Noemi de Luna2,3, Tomàs Pinós2,3.   

Abstract

McArdle disease is an autosomal-recessive disorder caused by inherited deficiency of the muscle isoform of glycogen phosphorylase (or "myophosphorylase"), which catalyzes the first step of glycogen catabolism, releasing glucose-1-phosphate from glycogen deposits. As a result, muscle metabolism is impaired, leading to different degrees of exercise intolerance. Patients range from asymptomatic to severely affected, including in some cases, limitations in activities of daily living. The PYGM gene codifies myophosphoylase and to date 147 pathogenic mutations and 39 polymorphisms have been reported. Exon 1 and 17 are mutational hot-spots in PYGM and 50% of the described mutations are missense. However, c.148C>T (commonly known as p.R50X) is the most frequent mutation in the majority of the studied populations. No genotype-phenotype correlation has been reported and no mutations have been described in the myophosphorylase domains affecting the phosphorylated Ser-15, the 280's loop, the pyridoxal 5'-phosphate, and the nucleoside inhibitor binding sites. A newly generated knock-in mouse model is now available, which renders the main clinical and molecular features of the disease. Well-established methods for diagnosing patients in laboratories around the world will shorten the frequent ∼20-year period stretching from first symptoms appearance to the genetic diagnosis.
© 2015 WILEY PERIODICALS, INC.

Entities:  

Keywords:  McArdle disease; PYGM; glycogenosis type V; mouse model

Mesh:

Substances:

Year:  2015        PMID: 25914343     DOI: 10.1002/humu.22806

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  21 in total

Review 1.  Gene therapy for glycogen storage diseases.

Authors:  Priya S Kishnani; Baodong Sun; Dwight D Koeberl
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

Review 2.  Skeletal muscle disorders of glycogenolysis and glycolysis.

Authors:  Richard Godfrey; Ros Quinlivan
Journal:  Nat Rev Neurol       Date:  2016-05-27       Impact factor: 42.937

Review 3.  Rodent models for resolving extremes of exercise and health.

Authors:  Fleur C Garton; Kathryn N North; Lauren G Koch; Steven L Britton; Gisela Nogales-Gadea; Alejandro Lucia
Journal:  Physiol Genomics       Date:  2015-09-22       Impact factor: 3.107

4.  Identification of a novel PYGM mutation in a McArdle disease patient misdiagnosed as hypokalemic periodic paralysis.

Authors:  R R Xie; Y B Yang; P Jin
Journal:  J Endocrinol Invest       Date:  2020-02-25       Impact factor: 4.256

5.  Manifesting heterozygotes in McArdle disease: a myth or a reality-role of statins.

Authors:  Judit Núñez-Manchón; Alfonsina Ballester-Lopez; Emma Koehorst; Ian Linares-Pardo; Daniëlle Coenen; Ignacio Ara; Carlos Rodriguez-Lopez; Alba Ramos-Fransi; Alicia Martínez-Piñeiro; Giuseppe Lucente; Miriam Almendrote; Jaume Coll-Cantí; Guillem Pintos-Morell; Alejandro Santos-Lozano; Joaquin Arenas; Miguel Angel Martín; Mauricio de Castro; Alejandro Lucia; Alfredo Santalla; Gisela Nogales-Gadea
Journal:  J Inherit Metab Dis       Date:  2018-06-20       Impact factor: 4.982

Review 6.  Biochemical and clinical aspects of glycogen storage diseases.

Authors:  Sara S Ellingwood; Alan Cheng
Journal:  J Endocrinol       Date:  2018-06-06       Impact factor: 4.286

7.  Clinical utility gene card for McArdle disease.

Authors:  Rhonda L Taylor; Mark Davis; Emma Turner; Astrid Brull; Tomás Pinos; Macarena Cabrera; Kristen J Nowak
Journal:  Eur J Hum Genet       Date:  2018-01-25       Impact factor: 4.246

8.  Myophosphorylase (PYGM) mutations determined by next generation sequencing in a cohort from Turkey with McArdle disease.

Authors:  Güldal Inal-Gültekin; Bahar Toptaş-Hekimoğlu; Zeliha Görmez; Özlem Gelişin; Hacer Durmuş; Bekir Ergüner; Hüseyin Demirci; Mahmut Ş Sağıroğlu; Yeşim Parman; Feza Deymeer; Hülya Yılmaz-Aydoğan; Sadrettin Pençe; Can Ebru Bekircan-Kurt; Ersin Tan; Sevim Erdem-Özdamar; Duran Üstek; Urs Giger; Oğuz Öztürk; Piraye Serdaroğlu-Oflazer
Journal:  Neuromuscul Disord       Date:  2017-06-16       Impact factor: 4.296

9.  Taking advantage of an old concept, "illegitimate transcription", for a proposed novel method of genetic diagnosis of McArdle disease.

Authors:  Ines Garcia-Consuegra; Alberto Blázquez; Juan Carlos Rubio; Joaquín Arenas; Alfonsina Ballester-Lopez; Adrián González-Quintana; Antoni L Andreu; Tomàs Pinós; Jaume Coll-Cantí; Alejandro Lucia; Gisela Nogales-Gadea; Miguel A Martín
Journal:  Genet Med       Date:  2016-02-25       Impact factor: 8.822

10.  Next-generation sequencing to estimate the prevalence of a great unknown: McArdle disease.

Authors:  Gisela Nogales-Gadea; Tomàs Pinós; Antoni L Andreu; Miguel A Martín; Joaquin Arenas; Alejandro Lucia
Journal:  Genet Med       Date:  2015-08       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.